Cantor Fitzgerald Reaffirms “Overweight” Rating for Taysha Gene Therapies (NASDAQ:TSHA)
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report)‘s stock had its “overweight” rating reiterated by Cantor Fitzgerald in a research note issued to investors on Monday,Benzinga reports. They currently have a $7.00 price objective on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 284.62% from the stock’s previous close. Several other equities […]
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report)‘s stock had its “overweight” rating reiterated by Cantor Fitzgerald in a research note issued to investors on Monday,Benzinga reports. They currently have a $7.00 price objective on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 284.62% from the stock’s previous close. Several other equities […]
